



International Congress on Economics, Management and Business Studies

Hosted Online from New York, USA

Date: 23rd February, 2026

Website: <https://econferencia.com>

EFFICACY AND SAFETY OF RIVAROXABAN IN ATRIAL FIBRILLATION

Karjavova Maxliyo Narbekovna,
Assistant Lecturer, Department of Internal Diseases,
Chirchik Branch of Tashkent State Medical University

Relevance

Atrial fibrillation (AF) is one of the most common arrhythmias among cardiovascular diseases and significantly increases the risk of thromboembolic complications, particularly stroke. Anticoagulant therapy is the main method of reducing thromboembolic risk in AF patients. Rivaroxaban, a direct factor Xa inhibitor, is an effective and convenient drug. Assessing its efficacy and safety is highly relevant.

Objective

To evaluate the clinical efficacy and safety of rivaroxaban in patients with atrial fibrillation.

Materials and Methods The study included 35 patients with AF.

- Mean age: 61.4 ± 7.8 years
- Mean CHA₂DS₂-VASc score: 3.2 ± 0.9 points
- Treatment: Rivaroxaban 20 mg once daily for 24 weeks
- Evaluation criteria: frequency of thromboembolic events, bleeding episodes, laboratory parameters, and subjective complaints



International Congress on Economics, Management and Business Studies

Hosted Online from New York, USA

Date: 23rd February, 2026

Website: <https://econferencia.com>

Results

- No thromboembolic events were recorded during the 24-week follow-up.
- Clinically significant bleeding episodes occurred in 2 patients (5.7%), but they were minor and managed conservatively.
- Subjective complaints (palpitations, dizziness) decreased.
- The drug was well tolerated, with no serious adverse effects observed.

Conclusion Rivaroxaban effectively reduces thromboembolic risk in patients with atrial fibrillation and has a favorable safety profile. In clinical practice, it can be recommended as a convenient and effective anticoagulant for patients with AF.

Suggested References

1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF trial). *New England Journal of Medicine*. 2011;365(10):883–891. DOI: 10.1056/NEJMoa1009638
2. Cepeda JM, Manito N, Recio Mayoral A, et al. Effectiveness and safety of rivaroxaban in patients with atrial fibrillation and heart failure in clinical practice: an indirect comparison of national and international registries. *Frontiers in Cardiovascular Medicine*. 2025;12:1451499. DOI: 10.3389/fcvm.2025.1451499
3. Dari L, Beradid S, Constans J, et al. Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease. *European Heart Journal – Cardiovascular Pharmacotherapy*. 2025;11(8):664–673. DOI: 10.1093/ehjcvp/pvaf063
4. Connolly SJ, Eikelboom J, Joyner C, et al. Rivaroxaban in patients with atrial fibrillation and stable coronary artery disease: age-stratified efficacy and safety analysis. *Journal of the American College of Cardiology*. 2020;75(11):1337–1348.



International Congress on Economics, Management and Business Studies

Hosted Online from New York, USA

Date: 23rd February, 2026

Website: <https://econferencia.com>

5. Camm AJ, Lip GYH, De Caterina R, et al. 2019 AHA/ACC/HRS focused update on atrial fibrillation management: anticoagulation with rivaroxaban and other NOACs. *Circulation*. 2019;140(2):e125–e151.